sinocelltech

Sinocelltech (Beijing Sino Cell Biotechnology Group Co., Ltd.; Shanghai Stock Exchange STAR Market code 688520) is a biopharmaceutical research and development company founded in 2002 by Dr. Xie Liangzhi. It develops and commercializes recombinant protein and monoclonal antibody therapeutics across oncology, autoimmune disease, and infectious disease, together with preventive vaccines including a recombinant 14-valent HPV vaccine and COVID-19 vaccines. The company has multiple marketed products in China and a pipeline of clinical-stage candidates. It publishes no public developer platform, API, or technical documentation surface.

sinocelltech is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Biopharmaceutical, Pharmaceutical, and Vaccines.

🌐 Visit website 📡 Source on GitHub
6.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotechnologyBiopharmaceuticalPharmaceuticalVaccinesMonoclonal AntibodiesOncologyChina

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 6.8/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.0 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/sinocelltech: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Sinocelltech Domain Security

TLSv1.2 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Company 1

The organization behind the API

Website
Website

Source (apis.yml)

apis.yml Raw ↑ 
aid: sinocelltech
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/sinocelltech.png
name: sinocelltech
description: Sinocelltech (Beijing Sino Cell Biotechnology Group Co., Ltd.; Shanghai Stock Exchange STAR Market code 688520)
  is a biopharmaceutical research and development company founded in 2002 by Dr. Xie Liangzhi. It develops and commercializes
  recombinant protein and monoclonal antibody therapeutics across oncology, autoimmune disease, and infectious disease, together
  with preventive vaccines including a recombinant 14-valent HPV vaccine and COVID-19 vaccines. The company has multiple marketed
  products in China and a pipeline of clinical-stage candidates. It publishes no public developer platform, API, or technical
  documentation surface.
url: https://raw.githubusercontent.com/api-evangelist/sinocelltech/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- qiming
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Biotechnology
- Biopharmaceutical
- Pharmaceutical
- Vaccines
- Monoclonal Antibodies
- Oncology
- China
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/sinocelltech-domain-security.yml
- type: Website
  url: https://sinocelltech.com
x-enrichment:
  date: '2026-07-21'
  status: minimal
  artifacts_added: 1
  pass: local-v1